How REDEMPLO Launch Momentum And SHASTA Phase 3 Milestones At Arrowhead Pharmaceuticals (ARWR) Has Changed Its Investment Story

Simply Wall St.05-25 04:18

Arrowhead Pharmaceuticals recently highlighted that it is entering a pivotal period, with new regulatory approvals for REDEMPLO, early commercial traction, and upcoming Phase 3 readouts for the SHASTA...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638077307?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-25 04:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638077307","market":"us","top_or_hot":-1,"title":"How REDEMPLO Launch Momentum And SHASTA Phase 3 Milestones At Arrowhead Pharmaceuticals (ARWR) Has Changed Its Investment Story","media":"Simply Wall St.","content":"<div>\n<p>Arrowhead Pharmaceuticals recently highlighted that it is entering a pivotal period, with new regulatory approvals for REDEMPLO, early commercial traction, and upcoming Phase 3 readouts for the SHASTA...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/how-redemplo-launch-momentum-and-shasta-phase-3-milestones-a\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How REDEMPLO Launch Momentum And SHASTA Phase 3 Milestones At Arrowhead Pharmaceuticals (ARWR) Has Changed Its Investment Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow REDEMPLO Launch Momentum And SHASTA Phase 3 Milestones At Arrowhead Pharmaceuticals (ARWR) Has Changed Its Investment Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-25 04:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/how-redemplo-launch-momentum-and-shasta-phase-3-milestones-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arrowhead Pharmaceuticals recently highlighted that it is entering a pivotal period, with new regulatory approvals for REDEMPLO, early commercial traction, and upcoming Phase 3 readouts for the SHASTA...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/how-redemplo-launch-momentum-and-shasta-phase-3-milestones-a\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/how-redemplo-launch-momentum-and-shasta-phase-3-milestones-a","article_id":"2638077307","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/how-redemplo-launch-momentum-and-shasta-phase-3-milestones-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2638077307","pubTimestamp":1779653939,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Arrowhead Pharmaceuticals recently highlighted that it is entering a pivotal period, with new regulatory approvals for REDEMPLO, early commercial traction, and upcoming Phase 3 readouts for the SHASTA-3 and SHASTA-4 trials in severe hypertriglyceridemia.\nAn interesting aspect is management’s emphasis on REDEMPLO’s multi-billion-dollar peak sales potential alongside a solid cash position to support its cardiometabolic pipeline as key data and commercialization milestones approach.\nWe’ll now...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","ARWR":"Arrowhead Research Corporation","BK4139":"生物科技"},"translate_title":"REDEMPLO在Arrowhead Pharmaceuticals(ARWR)推出Momentum和SHASTA第三阶段里程碑如何改变其投资故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1.5},"content_text":"Arrowhead Pharmaceuticals recently highlighted that it is entering a pivotal period, with new regulatory approvals for REDEMPLO, early commercial traction, and upcoming Phase 3 readouts for the SHASTA-3 and SHASTA-4 trials in severe hypertriglyceridemia. An interesting aspect is management’s emphasis on REDEMPLO’s multi-billion-dollar peak sales potential alongside a solid cash position to support its cardiometabolic pipeline as key data and commercialization milestones approach. We’ll now examine how the impending SHASTA-3 and SHASTA-4 Phase 3 data could reshape Arrowhead Pharmaceuticals’ broader investment narrative. We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementArrowhead Pharmaceuticals Investment Narrative RecapTo own Arrowhead today, you need to believe its RNAi cardiometabolic platform can turn current late stage programs into durable, commercial products, while the company manages rising costs and partner dependence. The latest REDEMPLO updates and upcoming SHASTA 3 and SHASTA 4 data keep those Phase 3 readouts as the key near term catalyst, and the main risk remains that trial or regulatory outcomes fall short and prolong losses. Among recent developments, the EMA CHMP positive opinion for REDEMPLO in familial chylomicronemia syndrome looks especially relevant. It reinforces the idea that Arrowhead is beginning to convert its science into real world approvals just as the severe hypertriglyceridemia data approach, which could matter for how investors judge the balance between current cash burn and the potential for a broader commercial franchise. Yet despite the excitement around REDEMPLO, investors should also be aware that rising operating costs and potential future dilution could... Read the full narrative on Arrowhead Pharmaceuticals (it's free!)Arrowhead Pharmaceuticals’ narrative projects $398.8 million in revenue and $64.0 million in earnings by 2028.Uncover how Arrowhead Pharmaceuticals' forecasts yield a $64.08 fair value, a 14% downside to its current price.Exploring Other PerspectivesARWR 1-Year Stock Price Chart Some of the most optimistic analysts were already modeling about US$1.1 billion in future revenue and US$179.9 million in earnings, yet this new REDEMPLO news and the cash burn risk they flagged could push those optimistic views, and your own, in very different directions.Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth over 2x more than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.Curious About Other Options?Every day counts. These free picks are already gaining attention. See them before the crowd does:Find 49 companies with promising cash flow potential yet trading below their fair value.Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638077307","isCrawlerRequest":true}